buoyantintelligence
  • 01Overview
  • 02Portfolio
  • 03Company Atlas
    • Buoyant book
    • All listed companies
  • 04Screener & valuation
  • 05House view
  • 06Markets
  • 07India top-down
  • 08Investors
  • 09Library & data
Release
August 2026 · rev 1
Opportunities PMS · Published
As at 31 Aug 2026 · IST₹ · ₹ cr · BSE 500 TRI
Present
Internal working platform. Published figures are extracted from the August 2026 source package and reviewed; reference prices and fundamentals are unlicensed working data, not for redistribution. Past performance is not indicative of future returns.
All listed companies/Akums Drugs and Pharmaceuticals Limited
03 /Listed universe · Healthcare · Pharmaceuticals

Akums Drugs and Pharmaceuticals Limited.

Value itCompareScreener.in ↗Tijori ↗NSE ↗BSE ↗
Snapshot

Healthcare · Pharmaceuticals

Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry powder injections, and gummies for therapeutic areas, such as antiinfectives, pain management, gastroenterology, orthopaedics, cardio-diabetic care, critical care, respiratory, and gynaecology. In addition, the company operates as pharmaceutical contract development and manufacturing company. Akums Drugs and Pharmaceuticals Limited was incorporated in 2004 and is based in Delhi, India.

Market cap
₹12,737 cr
P/E (TTM)
44.5
P/B (latest)
3.8
ROE (TTM)
7.7%
ROCE (TTM)
11.9%
Sales CAGR 3y
6.1%
PAT CAGR 3y
39.1%
Debt / equity
0.02x
Promoter
75.3%
Dividend yield
0.37%
Size
Micro
Codes
AKUMS · 544222
Price

₹819.55 · 29 Sept 2026

1M
+6.1%
3M
+31.2%
6M
+72.8%
YTD
+83.8%
1Y
+84.7%
3Y
—
5Y
—
vs 52w high
−0.5%

52-week ₹414.05 – ₹823.3 · ADTV ₹27.3 cr · price-only.

Trend

Sales and net profit by fiscal year, ₹ crore

Not in the Buoyant book: no house thesis or target is carried. Exchange masters, Tijori and the reference price feed as stated on each tab. All listed companies · NSE EQ